The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Molecular diversity in neuroendocrine tumors: A house divided.
 
Darshana Patil
Employment - Datar Cancer Genetics
Leadership - Datar Cancer Genetics
Stock and Other Ownership Interests - Datar Cancer Genetics
 
Udhayvir Grewal
No Relationships to Disclose
 
Ashok Vaid
Consulting or Advisory Role - Datar Cancer Genetics
 
Suresh Advani
No Relationships to Disclose
 
Shivam Shingla
No Relationships to Disclose
 
Ankur Varshney
No Relationships to Disclose
 
Andrew Gaya
Consulting or Advisory Role - Datar Cancer Genetics
 
Humaid Al-Shamsi
Employment - Burjeel Cancer Center
Leadership - Burjeel Cancer Center
Honoraria - Astellas Pharma; AstraZeneca/Merck; Ipsen; Lilly; Novartis; Roche; vitaris
Consulting or Advisory Role - AstraZeneca; Roche
Speakers' Bureau - Novartis
Research Funding - Merck; Merck
Travel, Accommodations, Expenses - Lilly; MSD
 
James Wilson
No Relationships to Disclose
 
Tanmoy Mandal
No Relationships to Disclose
 
Tim Crook
Consulting or Advisory Role - Datar Cancer Genetics
 
Aditya Shreenivas
Consulting or Advisory Role - Taiho Pharmaceutical (Inst)
Research Funding - Caris Life Sciences (Inst); Natera (Inst)
 
Rajan Datar
Employment - Datar Cancer Genetics
 
Sewanti Limaye
Consulting or Advisory Role - Datar Cancer Genetics
 
Razelle Kurzrock
Leadership - CureMatch; CureMetrix; XZOM
Stock and Other Ownership Interests - CureMatch; CureMetrix; IDbyDNA
Honoraria - AACR; Bicara Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; Foundation Medicine; LEK; Merck; NeoGenomics Laboratories; NeoMed; Pfizer; Roche; Turning Point Therapeutics; Wiley
Consulting or Advisory Role - Actuate Therapeutics; AstraZeneca; Bicara Therapeutics; Biological Dynamics; Caris Life Sciences; Daiichi Sankyo; Datar Genomics; Eisai; EMD Serono; EOM Pharmaceuticals; Gaido; Iylon; Jackson Laboratory for Genomic Medicine; LabCorp; Lanauria Therapeutics; Loxo; Merck; NeoGenomics Laboratories; NeoMed; Pfizer; Precirix; Precirix; Prosperdtx; Quanta Therapeutics; Recordati; Regeneron; Roche; Soluventis; TD2/Volastra; Turning Point Therapeutics; XBiotech
Speakers' Bureau - NeoGenomics Laboratories; Roche
Research Funding - Biological Dynamics (Inst); Boehringer Ingelheim (Inst); Debiopharm Group (Inst); Foundation Medicine (Inst); Genentech (Inst); Grifols (Inst); Guardant Health (Inst); Incyte (Inst); Konica Minolta (Inst); MedImmune (Inst); Merck Serono (Inst); NCI (Inst); OmniSeq (Inst); Pfizer (Inst); Sequenom (Inst); Sysmex (Inst); Takeda (Inst); Top Alliance BioScience (Inst)
Travel, Accommodations, Expenses - NCI SWOG; TargetCancer Foundation